NEW YORK — Maxim Biomedical said on Thursday that it has formed a marketing and distribution pact for its over-the-counter ClearDetect COVID-19 Antigen Home Test with Thomas Scientific.
The lateral flow assay, which received Emergency Use Authorization from the US Food and Drug Administration earlier this month, is designed to detect the SARS-CoV-2 nucleocapsid protein antigen in self- or adult-collected anterior nasal swab samples. It provides results within 15 minutes.
Under the terms of the deal, Swedesboro, New Jersey-based Thomas Scientific will offer the test in two formats: a two-test pack for at-home use and a bulk 25-test pack geared toward healthcare settings, schools, and other high-volume testing sites.
Financial and other terms of the agreement were not disclosed.
In late 2020, Rockville, Maryland-based Maxim received funding from the US National Institutes of Health's Rapid Acceleration of Diagnostics initiative to develop the test.